icon-folder.gif   Conference Reports for NaTaP  
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
No Significant Interaction Among Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir and Sofosbuvir
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Jennifer R. King1, Sandeep Dutta1, Dan Cohen3, Thomas J. Podsadecki3, Bifeng Ding2, Walid M. Awni1, and Rajeev M. Menon1 1AbbVie Inc., Clinical Pharmacology and Pharmacometrics, North Chicago, IL, 60064; 2AbbVie Inc., Biometrics, North Chicago, IL, 60064; 3AbbVie Inc., Infectious Disease Development, North Chicago, IL, 60064


A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With and Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection
A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With Sofosbuvir in DAA Treatment-experienced Adults With Chronic Hepatitis C Virus Infection